These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 10249304)
1. Additional standards for human blood and blood products, source plasma (human); amendment of storage temperature requirements: Food and Drug Administration, Final rule. Fed Regist; 1980 Dec; 45(236):80500-1. PubMed ID: 10249304 [TBL] [Abstract][Full Text] [Related]
2. Revisions to the requirements applicable to blood, blood components, and source plasma; confirmation in part and technical amendment. Food and Drug Administration, HHS. Direct final rule; confirmation in part and technical amendment. Fed Regist; 2001 Jan; 66(7):1834-7. PubMed ID: 11503754 [TBL] [Abstract][Full Text] [Related]
3. Revisions to the requirements applicable to blood, blood components, and source plasma. Final rule. Food and Drug Administration, HHS Fed Regist; 2001 Aug; 66(151):40886-90. PubMed ID: 11732557 [TBL] [Abstract][Full Text] [Related]
4. Biologics products; establishment registration and product listing for manufacturers of human blood and blood products; amendment to exempt certain transfusion services from registration--FDA. Final rule. Fed Regist; 1984 Aug; 49(171):34448-51. PubMed ID: 10299643 [TBL] [Abstract][Full Text] [Related]
5. Requirements for testing human blood donors for evidence of infection due to communicable disease agents. Final rule. Food and Drug Administration, HHS Fed Regist; 2001 Jun; 66(112):31146-65. PubMed ID: 11725786 [TBL] [Abstract][Full Text] [Related]
6. Current good manufacturing practices for blood and blood components: notification of consignees receiving blood and blood components at increased risk for transmitting HIV infection--FDA. Final rule. Fed Regist; 1996 Sep; 61(175):47413-23. PubMed ID: 10160337 [TBL] [Abstract][Full Text] [Related]
7. Revisions to the requirements applicable to blood, blood components, and source plasma. Department of Health and Human Services (HHS), Public Health Service (PHS), Food and Drug Administration (FDA). Direct final rule. Fed Regist; 1999 Aug; 64(160):45366-74. PubMed ID: 10558597 [TBL] [Abstract][Full Text] [Related]
8. Revisions to the requirements applicable to blood, blood components and source plasma; confirmation of effective date and technical amendment. Direct final rule; confirmation of effective date and technical amendment. Food and Drug Administration, HHS Fed Regist; 2008 Feb; 73(27):7463-4. PubMed ID: 18389917 [TBL] [Abstract][Full Text] [Related]
9. Revision to requirements for licensed Anti-Human Globulin and Blood Grouping Reagents. Food and Drug Administration, HHS. Direct final rule. Fed Regist; 2000 Dec; 65(239):77497-9. PubMed ID: 11503726 [TBL] [Abstract][Full Text] [Related]
10. Revisions to the requirements applicable to blood, blood components and source plasma. Direct final rule. Food and Drug Administration, HHS Fed Regist; 2007 Aug; 72(158):45883-88. PubMed ID: 17847577 [TBL] [Abstract][Full Text] [Related]
11. Revision of requirements applicable to albumin (human), plasma protein fraction (human), and immune globulin (human); confirmation in part and technical amendment. Food and Drug Administration, HHS. Direct final rule; confirmation in part and technical amendment. Fed Regist; 2000 Mar; 65(50):13678-9. PubMed ID: 11010647 [TBL] [Abstract][Full Text] [Related]
12. Over-the-counter human drugs; labeling requirements; final rule; technical amendment. Food and Drug Administration, HHS. Final rule; technical amendment. Fed Regist; 2000 Jan; 65(1):7-9. PubMed ID: 11010625 [TBL] [Abstract][Full Text] [Related]
13. Revision of requirements applicable to albumin (human), plasma protein fraction (human), and immune globulin (human). Food and Drug Administration, HHS. Direct final rule. Fed Regist; 1999 May; 64(93):26282-7. PubMed ID: 10558530 [TBL] [Abstract][Full Text] [Related]
14. Topical antifungal drug products for over-the-counter human use; amendment of final monograph. Food and Drug Administration, HHS. Final rule. Fed Regist; 2000 Aug; 65(168):52302-5. PubMed ID: 11067736 [TBL] [Abstract][Full Text] [Related]
15. Exemption of certain transfusion services and clinical laboratories from registration: Food and Drug Administration. Final rule. Fed Regist; 1980 Dec; 45(251 Pt 1):85727-30. PubMed ID: 10298064 [TBL] [Abstract][Full Text] [Related]
16. Additional standards for human blood and blood products; source plasma (human)--Food and Drug Administration. Final rule. Fed Regist; 1981 Nov; 46(226):57480-1. PubMed ID: 10253366 [TBL] [Abstract][Full Text] [Related]
17. Applications for Food and Drug Administration application approval to market a new drug; revision of postmarketing reporting requirements. Final rule. Food and Drug Administration, HHS Fed Regist; 2007 Oct; 72(201):58993-9000. PubMed ID: 17966558 [TBL] [Abstract][Full Text] [Related]
18. Revisions to labeling requirements for blood and blood components, including source plasma. Final rule. Food and Drug Administration, HHS Fed Regist; 2012 Jan; 77(1):7-18. PubMed ID: 22242229 [TBL] [Abstract][Full Text] [Related]
19. Biological products: reporting of biological product deviations in manufacturing. Food and Drug Administration, HHS. Final rule. Fed Regist; 2000 Nov; 65(216):66621-35. PubMed ID: 11503696 [TBL] [Abstract][Full Text] [Related]
20. Revision of requirements applicable to albumin (human), plasma protein fraction (human), and immune globulin (human). Food and Drug Administration, HHS. Final rule. Fed Regist; 2000 Aug; 65(167):52016-8. PubMed ID: 11067735 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]